Loading
Stage shift means finding more cancers early and fewer late; it is the measurable goal of screening.
Stage shift is the observable goal of screening: more cancers found at an early stage and fewer found late. It is the primary endpoint of the NHS-Galleri trial, defined as a reduction in the incidence of stage III and IV disease. A stage shift does not by itself prove that a screening test saves lives, because lead-time bias, length-time bias and overdiagnosis can all produce one, but it is a necessary precondition for any such benefit. The term is linked to the Multi-cancer early detection (MCED) and Mammography & tomosynthesis technologies and is referenced by UKCTOCS, High-risk pancreatic surveillance, the early detection roadmap, the bottleneck on late-found cancers and an idea on letting MCED trials read out on late-stage incidence.
Showing the technology this term belongs to: Multi-cancer early detection (MCED).
For someone offered the test, these are the numbers that describe what a result means in an NHS population: about 1 in 100 tests came back positive each year, between 46 and 58 in 100 positives were cancer, and a negative result left about 1 in 100 with an undetected cancer within the year. The test found between a quarter and a third of all cancers diagnosed in a screening round, and about half to two thirds of the 12 cancer types it was designed to find. Whether finding them this way reduces late-stage diagnoses is the primary question, and this paper says only that the answer was no; the primary-endpoint paper had not appeared on Europe PMC by 23 September 2026.
A multi-cancer blood test can be run in ordinary clinics, and most positive results can be resolved with imaging. But six in ten positives are false alarms that take months to resolve, and the test misses most cancers. Whether it reduces late-stage cancer or deaths is unknown; that requires randomised trials.
NHS-Galleri is the trial that will decide whether a blood test for many cancers at once should be offered by a health system. Its endpoint is a reduction in late-stage cancer rather than deaths, so even a positive result leaves the mortality question to be settled by longer follow-up.
A blood test can find early, treatable cancers in people who feel well, including cancers for which no screening exists. It is not a replacement for mammography or colonoscopy but a possible addition. Larger randomised trials are needed to show benefit outweighs harm.
Lung screening works when it uses volumetric nodule management, and it works against a no-screening control. The protocol underpins the UK Targeted Lung Health Check programme and European recommendations. Benefit in women remains less precisely estimated.
For people with a heavy smoking history, an annual low-dose CT scan is one of the few screening tests proven to reduce cancer deaths. Most abnormal scans are not cancer, so screening must be paired with careful nodule management. It does not apply to never-smokers or light smokers.
Shares Breath and volatile-organic-compound detection, Vanguard Study (NCI Cancer Screening Research Network), CCGA: the Circulating Cell-free Genome Atlas behind the Galleri methylation test, New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score).
Shares Vanguard Study (NCI Cancer Screening Research Network), CCGA: the Circulating Cell-free Genome Atlas behind the Galleri methylation test, Let MCED trials read out on late-stage incidence, with mortality follow-up mandated, New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score).
Shares Vanguard Study (NCI Cancer Screening Research Network), Let MCED trials read out on late-stage incidence, with mortality follow-up mandated, A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early, NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test.
Shares CCGA: the Circulating Cell-free Genome Atlas behind the Galleri methylation test, Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial, NHS-Galleri, Multi-cancer early detection (MCED).
Shares NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms, NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers, Overdiagnosis, Early detection roadmap: organ screening → blood tests for many cancers.
Shares NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test, Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial, NHS-Galleri, Multi-cancer early detection (MCED).
Shares Require stage-shift or interval-cancer endpoints for AI in cancer screening, Molecular indolence classifiers bundled with every screening programme, A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early, NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test.
Shares Total-body PET for screening and ultra-low-dose imaging, Early detection, A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early, Early detection roadmap: organ screening → blood tests for many cancers.